Essential Tremor Treatment With Ultrasound - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The essential tremor treatment with ultrasound market size is expected to grow from USD 262.43 million in 2025 to USD 292.40 million in 2026 and is forecast to reach USD 502.10 million by 2031 at 11.42% CAGR over 2026-2031. This report is segmented by Indication (Hand, and More), Treatment Type (MR-Guided Focused Ultrasound Thalamotomy, and More), End User (Hospitals, Neurology Clinics, and More), Patient Demographics (Adult and Pediatric Patients), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). Forecasts are Provided in Terms of Value (USD).

Global Essential Tremor Treatment With Ultrasound Market Trends and Insights

Increasing Prevalence of Essential Tremor and Aging-Linked Patient Pool

Essential tremor creates a large clinical need, although treatment use remains below the number of people living with the condition. A 2024 U.S. claims study identified 1.1 million adults with a diagnosed essential tremor classification. The broader case definition in the same study increased the figure to 2.1 million adults. The essential tremor treatment with ultrasound market draws its future patient base from the difference between diagnosed cases and people receiving adequate care. Pooled prevalence was 1.3% across all ages and reached 5.8% among adults aged 65 years and older. Prevalence rose by 74% with each additional decade of age in the available evidence base.

Medication does not control tremor for an estimated 30% to 50% of patients, leaving a recurring group of potential procedural candidates. This supports referrals into movement-disorder and functional-neurosurgery services as patients age. Misclassification as physiologic tremor or early Parkinson’s disease can delay specialist assessment and treatment selection. Germany recorded an increase in essential tremor incidence from 10.7 to 24.8 per 100,000 people between 2010 and 2021. The increase reflected stronger awareness as well as demographic aging. The essential tremor treatment with ultrasound market therefore has a durable demand base in North America, Europe, and East Asia, where older populations increasingly enter specialist care.

Patient Preference for Incisionless, Implant-Free Treatment

MR-guided focused ultrasound offers an outpatient alternative to procedures that require implanted hardware or open surgery. MRgFUS thalamotomy surpassed deep brain stimulation as the most common procedural intervention for essential tremor in the United States. More than 20,000 MRgFUS neurosurgical procedures had been performed worldwide by 2024. The essential tremor treatment with ultrasound market gains from the appeal of same-day tremor improvement for appropriate patients. The procedure also avoids the maintenance and replacement requirements associated with implanted stimulation systems. These features can matter to patients who have delayed intervention because they were concerned about surgery.

Five-year data showed a 51.9% improvement in tremor and motor function after unilateral MRgFUS treatment. The same study found that 87% of subjects retained at least 25% improvement, while 52.2% retained at least 50% improvement at 5 years. It reported that 60.3% of related adverse events resolved within 6 months. No new safety signals emerged beyond the first year in that dataset. Public disclosure of successful treatment by Lord Julian Fellowes in September 2025 increased awareness of incisionless options among patients. The essential tremor treatment with ultrasound market can benefit when awareness encourages patients to seek a specialist opinion earlier.

High Capital Cost of MR-Guided Focused Ultrasound Systems

An MRgFUS installation requires USD 2.2 million to USD 2.8 million for the focused ultrasound system alone. This excludes the MRI platform and concentrates adoption in academic medical centers and large hospital networks. Norton Healthcare Foundation committed USD 2.8 million in October 2024 to establish Kentucky’s first center. The essential tremor treatment with ultrasound market faces a slower rollout where hospitals cannot use philanthropy, public funding, or large capital budgets. Smaller hospitals and ambulatory surgical centers usually have less ability to absorb the initial investment. This limits how quickly treatment access can spread beyond regional referral centers.

Annual service contracts add USD 185,000, while disposable kits cost USD 3,300 per procedure. Site preparation costs USD 35,000 to USD 50,000, adding to the total program commitment. Medicare facility reimbursement was USD 12,388 per procedure in 2025. Typical volumes of 100 to 150 cases per year can lead to extended payback periods. The burden is especially relevant in India and Brazil, where system purchases may require donor support or government subsidy. The Vattikuti Foundation donated a system to AIIMS New Delhi for an institutional program in 2025.

Other drivers and restraints analyzed in the detailed report include:

• Expanding Clinical Evidence and Bilateral Treatment Adoption
• Reimbursement Expansion for Medication-Refractory Essential Tremor
• Limited Availability of Specialized Neurosurgical Teams

Segment Analysis

Head tremor held 42.5% of the essential tremor treatment with ultrasound market share in 2025. Its leading position reflects the visible and socially disruptive effects of cervical and cephalic tremor. Symptoms can affect eating, social interaction, and work activities. These effects can lead patients to seek a specialist assessment sooner. The ventral intermediate thalamus is the main target for MRgFUS treatment. That target has relevance for tremor affecting multiple body regions. The segment, therefore, includes patients with upper-extremity and axial manifestations. Head tremor has remained important to the procedure mix because of its effect on daily function.

Hand tremor is forecast to grow at a 12.9% CAGR through 2031. The original U.S. clearance addressed unilateral thalamotomy for medication-refractory hand tremor. The staged bilateral pathway can support a later procedure for tremor on the opposite side. Bilateral adoption grew 69% from 2023 to 2024. This allows a sequential treatment cycle for patients with tremor in both hands. Voice tremor, trunk tremor, upper extremity tremor, and lower extremity tremor are smaller indication groups. Their future use depends on broader diagnostic awareness and expanding clinical evidence. The essential tremor treatment with ultrasound market can widen gradually as referral patterns recognize these different functional needs.

High-intensity focused ultrasound held 58.7% of the essential tremor treatment with ultrasound market share in 2025. It remains the main treatment modality in settings with established MRI workflows and procedural registries. Hospital teams are familiar with its clinical process and treatment planning requirements. This familiarity supports consistent use in developed treatment markets. MR-guided focused ultrasound thalamotomy remains the established regulatory approach in the United States and Europe. Real-time thermal imaging supports lesion control during the procedure. This feature remains central to clinical confidence and institutional governance. The essential tremor treatment with ultrasound industry relies on such validated pathways as new modalities develop.

Ultrasound-guided focused ultrasound is forecast to grow at a 13% CAGR through 2031. Facilities are exploring approaches that may reduce dependence on high-field MRI suite access. MRI scheduling can constrain capacity when multiple clinical departments compete for time. This is relevant in Asia-Pacific and lower-resource settings. Exablate Prime received FDA approval and CE Mark for use with select Philips MRI systems in November 2024. The approval broadened the potential hospital base for MR-guided treatment. Other treatment types include experimental transcranial neuromodulation and low-frequency protocols. The essential tremor treatment with ultrasound market will continue to compare access benefits with the value of real-time thermal monitoring.

Complete Report Scope:

• By Indication
  • Hand Tremor
  • Head Tremor
  • Voice Tremor
  • Trunk Tremor
  • Upper Extremity Tremor
  • Lower Extremity Tremor
• By Treatment Type
  • MR-Guided Focused Ultrasound Thalamotomy
  • High-Intensity Focused Ultrasound
  • Ultrasound-Guided Focused Ultrasound
  • Other Treatment Types
• By End User
  • Hospitals
  • Specialty Neurology Clinics
  • Ambulatory Surgical Centers
  • Other End Users
• By Patient Demographics
  • Adult Patients
  • Pediatric Patients
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 41.7% of global revenue in 2025. The region benefits from FDA clearance, Medicare facility coverage, and an established clinical base. Staged bilateral use rose 69% from 2023 to 2024. That increase adds second-procedure volume for suitable patients. U.S. coding under CPT 61715 and APC 5463 provided greater billing clarity in 2025. Canada gained a Medical Device License for Exablate Prime in February 2026. The approval included select Philips MRI platforms and may support wider use by compatible centers.

Europe is expanding reimbursement arrangements across national markets. NHS England has commissioned MRgFUS thalamotomy at 4 specialist centers since 2021. Its annual cap of 150 patients remains below the potential eligible population. France published national reimbursement in March 2026 after a positive HAS benefit assessment. The policy provides a clearer route for hospitals to offer care under an outcomes registry. Germany enabled routine reimbursement for HIFU therapy at centers including Freiburg University Hospital. Spain and Italy continue to contribute to the region’s treatment base under CE Mark authorization.

Asia-Pacific is forecast to grow at a 12.5% CAGR through 2031. Japan has national insurance coverage for MRgFUS under billing code K154-4. South Korea has approved MRgFUS for essential tremor under national device regulations. India established an institutional focused ultrasound program at AIIMS New Delhi through a 2025 partnership involving Insightec and the Vattikuti Foundation. The program also serves as a training route for South Asian clinicians. China’s domestic HIFU manufacturers are expanding neurology application portfolios. The essential tremor treatment with ultrasound market remains early-stage in the Middle East and Africa and South America, where private-pay use and institutional partnerships are still building access.

List of Companies Covered in this Report:

• Alpinion Medical Systems Co., Ltd.
• Boston Scientific
• Chongqing Haifu Medical Technology Co., Ltd.
• ClearPoint Neuro, Inc.
• Elekta AB (publ)
• EDAP TMS S.A.
• FUS Instruments
• Insightec Ltd.
• Koninklijke Philips
• Medtronic
• Monteris Medical Corporation
• Profound Medical
• Siemens Healthineers
• GE HealthCare Technologies Inc.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support